

Review

Open Access

## The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi

Vivi Joosten\*, Christien Lokman, Cees AMJJ van den Hondel and Peter J Punt

Address: TNO Nutrition and Food Research, Department of Applied Microbiology and Gene Technology, P.O. Box 360, 3700 AJ Zeist, The Netherlands

Email: Vivi Joosten\* - joosten@voeding.tno.nl; Christien Lokman - lokman@voeding.tno.nl; Cees AMJJ van den Hondel - hondel@voeding.tno.nl; Peter J Punt - p.punt@voeding.tno.nl

\* Corresponding author

Published: 30 January 2003

Received: 9 December 2002

*Microbial Cell Factories* 2003, 2:1

Accepted: 30 January 2003

This article is available from: <http://www.microbialcellfactories.com/content/2/1/1>

© 2003 Joosten et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

### Abstract

In this review we will focus on the current status and views concerning the production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. We will focus on single-chain antibody fragment production (scFv and  $V_{HH}$ ) by these lower eukaryotes and the possible applications of these proteins. Also the coupling of fragments to relevant enzymes or other components will be discussed. As an example of the fusion protein strategy, the 'magic bullet' approach for industrial applications, will be highlighted.

### Introduction


Antibodies (also called immunoglobulins) are glycoproteins, which specifically recognise foreign molecules. These recognised foreign molecules are called antigens. When antigens invade humans or animals, an immunological response is triggered which involves the production of antibodies by B-lymphocytes. By this immunological response, microorganisms, larger parasites, viruses and bacterial toxins can be rendered harmless. The unique ability of antibodies to specifically recognise and bind with high affinity to virtually any type of antigen, made them interesting molecules for medical and scientific research.

In 1975 Köhler and Milstein developed the monoclonal antibody technology [1] by immortalising mouse cell lines that secreted only one single type of antibody with unique antigen specificity, called monoclonal antibodies (mAbs). With this technology, isolation and production of mAbs against protein, carbohydrate, nucleic acids and hapten antigens was achieved. The technology resulted in a rapid development of the use of antibodies in diagnos-

tics (*e.g.* pregnancy tests; [2]), human therapeutics and as fundamental research tools.

More applications outside research and medicine can be considered, such as consumer applications. Examples are the use of antibodies in shampoos to prevent the formation of dandruff [3] or in toothpaste to protect against tooth decay caused by caries [4]. For these purposes large quantities of antibodies are required. However, for these applications on a larger scale there were some major problems concerning the expensive production system based on mammalian expression, the difficulty of producing antibodies in bulk amounts and the low stability and solubility of some antibodies under specific (harsh) conditions.

In this review we will discuss the possibilities of large-scale production of antibodies and fragments thereof by relevant expression systems. Requirements are that the system used for production is cheap, accessible for genetic modifications, easily scaled up for greater demands and safe for use in consumer applications.

**Figure 1**

Schematic representation of the structure of a conventional IgG and fragments that can be generated thereof. The constant heavy-chain domains  $C_{H1}$ ,  $C_{H2}$  and  $C_{H3}$  are shown in yellow, the constant light-chain domain ( $C_L$ ) in green and the variable heavy-chain ( $V_H$ ) or light-chain ( $V_L$ ) domains in red and orange, respectively. The antigen binding domains of a conventional antibody are Fabs and Fv fragments. Fab fragments can be generated by papain digestion. Fvs are the smallest fragments with an intact antigen-binding domain. They can be generated by enzymatic approaches or expression of the relevant gene fragments (the recombinant version). In the recombinant single-chain Fv fragment, the variable domains are joined by a peptide linker. Both possible configurations of the variable domains are shown, i.e. the carboxyl terminus of  $V_H$  fused to the N-terminus of  $V_L$  and vice versa.

First, structure and characteristics of antibodies and antibody fragments generated thereof will be discussed, followed by the impact of recombinant DNA technology and antibody engineering techniques on the generation and modification of antibodies and antibody fragments. The modification of antibodies is of major interest since changes in their functionality and physico-chemical properties will broaden their application area. For most applications only the antigen-binding site of the native antibody molecule is required and even preferred. By the development of recombinant DNA technology and the increasing knowledge on the structure of antibody molecules created the opportunity to clone and engineer smaller fragments of antibody genes [5,6] and subsequent alter their functions, for example improve the affinity for their antigen. Besides that, recombinant DNA technology provides the possibility to generate fusion proteins or 'Magic bullets', consisting of an antibody fragment fused to an effector molecule.

In this review the various expression systems for these type of protein will be outlined. We will detail on using yeasts

and filamentous fungi as suitable expression systems for antibody fragments and antibody fusion proteins.

## Antibodies and their unique antigen binding domains

### Whole antibodies

In vertebrates five immunoglobulin classes are described (IgG, IgM, IgA, IgD and IgE), which differ in their function in the immune system. IgGs are the most abundant immunoglobulins in the blood and these molecules have a molecular weight of approximately 160 kDa. They have a basic structure of two identical heavy (H) chain polypeptides and two identical light (L) chain polypeptides (Figure 1). The H and L chains, which are all  $\beta$ -barrels, are kept together by disulfide bridges and non-covalent bonds (for a review about antibody structure see [7]). The chains themselves can be divided in variable and constant domains. The variable domains of the heavy and light chain ( $V_H$  and  $V_L$ ) which are extremely variable in amino acid sequences are located at the N-terminal part of the antibody molecule.  $V_H$  and  $V_L$  together form the unique antigen-recognition site. The amino acid sequences of the

remaining C-terminal domains are much less variable and are called C<sub>H</sub>1, C<sub>H</sub>2, C<sub>H</sub>3 and C<sub>L</sub>.

#### *Fc fragment*

The non-antigen binding part of an antibody molecule, the constant domain Fc mediates several immunological functions, such as binding to receptors on target cells and complement fixation (triggering effector functions that eliminate the antigen). The Fc domain is not essential for most biotechnical applications, relying on antigen binding. The Fc fragment, which is glycosylated, can have different effector functions in the different classes of immunoglobulins.

#### *Antigen binding region*

The unique antigen-binding site of an antibody consists of the heavy and light chain variable domains (V<sub>H</sub> and V<sub>L</sub>). Each domain contains four conserved framework regions (FR) and three regions called CDRs (complementarity determining regions) or hypervariable regions. The CDRs strongly vary in sequence and determine the specificity of the antibody. V<sub>L</sub> and V<sub>H</sub> domains together form a binding site, which binds a specific antigen.

#### **Antibody fragments generated thereof**

Several functional antigen-binding antibody fragments could be engineered by proteolysis of antibodies (papain digestion, pepsin digestions or other enzymatic approaches), yielding Fab, Fv or single domains (Figure 1).

#### *Fab fragments*

Fab fragments (fragment antigen binding) are the antigen-binding domains of an antibody molecule, containing V<sub>H</sub> + C<sub>H</sub>1 and C<sub>L</sub> + V<sub>L</sub>. Between C<sub>L</sub> and C<sub>H</sub>1 an interchain disulfide bond is present. The molecular weight of the heterodimer is usually around 50 kDa [8]. Fab fragments can be prepared by papain digestions of whole antibodies.

#### *Fv fragments*

The minimal fragment (~30 kDa) that still contains the whole antigen-binding site of a whole IgG antibody is composed of both the variable heavy chain (V<sub>H</sub>) and variable light chain (V<sub>L</sub>) domains. This heterodimer, called Fv fragment (for fragment variable) is still capable of binding the antigen [9]. Normally, native Fv fragments are unstable since the non-covalently associated V<sub>L</sub> and V<sub>H</sub> domains tend to dissociate from one another at low protein concentrations.

#### *Single domains*

Single domain antigen binding fragments (dAbs) or V<sub>H</sub>s were generated in the past [10,11]. They have good antigen-binding affinities, but exposure of the hydrophobic surface of the V<sub>H</sub> to the solvent, which normally interacts with the V<sub>L</sub>, causes a sticky behaviour of the isolated V<sub>H</sub>s.

It turned out to be difficult to produce them in soluble form, although replacement of certain amino acids increased solubility of these single domains (see also **Llama Heavy-chain antibody fragments**) Besides that, their affinity for the antigen was much less compared with other antibody fragments [12].

#### **Heavy-chain antibodies in Camelidae**

In 1993 Hamers-Casterman *et al.* [13] discovered a novel class of IgG antibodies in *Camelidae* (camels, dromedaries and llamas). These antibodies are devoid of light chains and therefore called 'heavy-chain' IgGs or HCAb (for heavy-chain antibody; Figure 2). HCABs have a molecular weight of ~95 kDa instead of the ~160 kDa for conventional IgG antibodies. Their binding domains consist only of the heavy-chain variable domains, referred to as V<sub>HHS</sub> [14] to distinguish it from conventional V<sub>H</sub>s. Since the first constant domain (C<sub>H</sub>1) is absent (spliced out during mRNA processing due to loss of a splice consensus signal; [15,16]), the variable domain (V<sub>HHS</sub>) is immediately followed by the hinge region, the C<sub>H</sub>2 and the C<sub>H</sub>3 domains. Although the HCABs are devoid of light chains, they have an authentic antigen-binding repertoire. The current knowledge about the genetic generation mechanism of HCABs is reviewed by Nguyen *et al.* [17,18].


#### **Recombinant antibodies, antibody fragments and antibody fusion proteins**

The development and applications of recombinant DNA technology led to the design of several new antibodies and antibody fragments. Firstly, functionalities of these proteins may be altered resulting in novel and improved functions. One of the possible applications of recombinant whole antibodies is the use in human therapeutics (see also **Recombinant whole antibodies**). Secondly, smaller antibody fragments may be synthesised having the advantage over whole antibodies in applications requiring tissue penetration and rapid clearance from the blood or kidney. Moreover, the use of recombinant expression systems could also be the solution for large-scale production of antibody (fragments).

#### **Recombinant whole antibodies**

The development of human(ised) antibody molecules is mostly aimed at reduction of unwanted immunological properties in medical applications [19]. Repeated doses of foreign (murine) antibody molecules could lead to an immune response in patients recognising the mouse antibody as foreign. This so-called HAMA (human anti-mouse antibody) response can lead to severe health problems.

Two strategies are developed to reduce the antigenicity of therapeutic antibodies (see also [20]). One of these strategies is chimerisation. In this case the constant murine do-

**Figure 2**

Schematic representation of the structure of a conventional IgG, a heavy-chain IgG antibody and the variable heavy-chain antibody fragment ( $V_{HH}$ ) that can be generated of the latter. Heavy-chain antibodies found in llama and camel are only composed of heavy-chains and lack the light chain completely, as shown in this Figure. The antigen-binding domain consists of only the  $V_H$  domain, which is referred to as  $V_{HH}$  (variable heavy-chain antibody fragment), to distinguish it from a normal  $V_H$ . The constant heavy-chain domains  $C_{H1}$ ,  $C_{H2}$  and  $C_{H3}$  are shown in yellow, the constant light-chain domain ( $C_L$ ) in green and the variable heavy-chain ( $V_H$  or  $V_{HH}$ ) or light-chain ( $V_L$ ) domains in red and orange, respectively.

mains are replaced by human constant domains [21,22]. The second strategy is grafting of only the murine CDRs onto existing human antibody framework regions, which is called humanisation [22].

At present there are more than 10 recombinant antibodies approved by the US Food and Drug Administration (FDA) for use in medicine and many more are in a late stage of clinical trials. FDA approved recombinant mAbs are *e.g.* Herceptin™ (Genetech, San Francisco, CA), which targets and blocks the growth factor Her2 on the surface of breast cancer cells and Rituxan™ (IDEC Pharmaceuticals Inc., San Diego, CA) used against non-Hodgkin's lymphoma (see for more examples [23,24]). The use of recombinant antibodies for medical purposes does not require a cheap large-scale production process *per se*, since only a limited amount of pure preparations is needed.

#### **Production of recombinant antibody fragments by *Escherichia coli***

Much work on antibody fragment production has been focussed on *Escherichia coli* as an expression system (reviewed in [25]). The advantage of this system is the ability to produce proteins in relative large amounts. Besides that, *E. coli* is easily accessible for genetic modifications, requires simple inexpensive media for rapid growth and they can easily be cultured in fermentors permitting large-scale production of proteins of interest. Several antibody fragments have been produced in functional form (*e.g.* [8,9,26,27]) and expression of relevant gene segments also permitted the production of the recombinant antibody fragments. The problem of stability has been tackled by generation of single-chain Fv (scFv) or disulfide stabilised Fv (dsFv) fragments.

#### **Selection of antibody fragments with improved functionalities**

In 1990 McCafferty *et al.* [28] showed that antibody fragments could be displayed on the surface of filamentous

phages, called phage-display. This technology is based on the fusion of the antibody variable genes to a phage coat protein gene (*e.g.* [20]). After displaying an antibody fragment on the protein surface of the phage, antigen specific phages can be selected and enriched by multiple rounds of affinity panning (*e.g.* reviewed in [29,30]). This technique makes it possible to select phages that bind almost any antigen, including those previously considered to be difficult, such as self-antigens or cell surface proteins.

Libraries can be prepared from variable genes isolated from immunised animals, non-immunised sources (naïve libraries, thus avoiding the need for immunisation) or even (semi-) synthetic libraries can be constructed. The V genes can be subjected to random mutagenesis, chain or DNA shuffling methods [31], mimicking the natural hypermutation mechanism.

#### **Single-chain Fv fragments and multimers**

An attractive recombinant antibody fragment is the single-chain Fv (scFv) fragment (reviewed in [32,33]). It has a high affinity for its antigen and can be expressed in a variety of hosts [34]. These and other properties make scFv fragments not only applicable in medicine (reviewed in [35]), but also of potential for biotechnological applications. In the scFv fragment the  $V_H$  and  $V_L$  domains are joined with a hydrophilic and flexible peptide linker, which improves expression and folding efficiency [36,37]. Usually linkers of about 15 amino acids are used, of which the  $(Gly_4Ser)_3$  linker has been used most frequently [35]. Unfortunately, some scFv molecules have a reduced affinity compared to the parental whole antibody or Fab molecule [12,38,39]. Besides that, scFv molecules can be easily proteolytically degraded, depending on the linker used [40]. With the development of genetic engineering techniques these limitations could be practically overcome by research focussed on improvement of function and stability, as discussed in [32]. An example is the generation of disulfide-stabilised Fv fragments where the  $V_H$ - $V_L$  dimer is stabilised by an interchain disulfide bond [38,41,42]. Cysteines are introduced at the interface between the  $V_L$  and  $V_H$  domains, forming a disulfide bridge, which holds the two domains together (reviewed in [43]).

Dissociation of scFvs results in monomeric scFvs, which can be complexed into dimers (diabodies), trimers (triabodies) or larger aggregates ([44], reviewed in [45]). The simplest designs are diabodies that have two functional antigen-binding domains that can be either similar (bivalent diabodies) or have specificity for distinct antigens (bispecific diabodies). These bispecific antibodies allow for example the recruitment of novel effector functions (such as cytotoxic T cells) to the target cells, which make them very useful for applications in medicine (reviewed in [46,47]).

#### **Llama Heavy-chain antibody fragments ( $V_{HHs}$ )**

The other type of interesting antibody fragments are  $V_{HHs}$  (see Figure 2) comprising the smallest available intact antigen-binding fragment (~15 kDa, 118–136 residues [48,49]). The affinities found for  $V_{HHs}$  were in the nanomolecular range and comparable with those of Fab and single chain Fv (scFv) fragments [50,51]. Besides that  $V_{HHs}$  are highly soluble and more stable than the corresponding derivatives of scFv and Fab fragments [50,52].  $V_{HHs}$  carry amino acid substitutions that make them more hydrophilic and prevent the prolonged interaction with BiP (Immunoglobulin heavy-chain binding protein), which normally binds to the H-chain in the Endoplasmic Reticulum (ER) during folding and assembly, until it is displaced by the L-chain [53]. There are indications that this increased hydrophilicity improves secretion of the  $V_{HHs}$  from the ER. Hence, production of  $V_{HHs}$  in commercially attractive microorganisms may be favourable.

Several ways are described to obtain functional  $V_{HHs}$ : from proteolysed HCAb of an immunised camelid, direct cloning of  $V_{HH}$  genes from B-cells of an immunised camelid resulting in recombinant  $V_{HHs}$  or from naïve or synthetic libraries [49].  $V_{HHs}$  with desired antigen specificity could be selected by phage display (see **Selection of antibody fragments with improved functionalities**). Using  $V_{HHs}$  in phage display is much simpler and more efficient as compared with Fabs or scFvs, since only one domain needs to be cloned and expressed to obtain a functional antigen-binding fragment [52,54].

As already noted before (see **Antibody fragments generated thereof**), classical  $V_H$ s were difficult to produce in soluble form. To improve their solubility and prevent non-specific binding, residues located on the  $V_L$  side of  $V_H$ s were replaced by ' $V_{HH}$ -like' residues, mimicking the more soluble  $V_{HH}$  fragments. This process has been termed camelisation [55–57] and these camelised  $V_H$  fragments, particularly those based on the human framework, are expected to have significant advantages for therapeutic purposes in humans (reviewed in [58]).

#### **Fusion proteins ('Magic bullets')**

A completely new use of the binding capacity of antibody fragments is the design of a fusion approach, in which an effector protein is coupled to an antigen recognising antibody fragment. In human medicine this approach is referred to 'Magic bullet'. All kinds of molecules can be used as effector molecule only limited by the imagination. The gene encoding the effector may be directly fused to the gene of the antibody fragment of interest, resulting in novel bifunctional proteins [59]. Examples of the use of this approach will be given in the section **Antibody fragments and antibody fusion proteins for large-scale applications and consumer products**.

**Table 1: Extracellular production of antibody fragments in prokaryotic expression systems.**

Strains	Characteristics	Food grade	Production yields	References
<i>Lactobacillus zeae</i>	Gram <sup>+</sup>	yes	scFv, ND* (secreted/cell-bound)	[91]
<i>Bacillus subtilis</i>	Gram <sup>+</sup>	yes	10 to 15 mg/L scFv (secreted)	[143,144]
<i>Streptomyces lividans</i>	Gram <sup>+</sup>	yes	1 mg/L Fv fragment (secreted)	[145,146]
<i>Staphylococcus carnosus</i>	Gram <sup>+</sup>	yes	5–10 mg/L V <sub>H</sub> domain (secreted)	[147]
<i>Proteus mirabilis</i>	Gram <sup>-</sup>	no	40 to 200 mg/L scFv (secreted)	[148,149]
<i>Escherichia coli</i>	Gram <sup>-</sup>	no	Several fragments (inclusion bodies/periplasmic space)	[25,34]

\*ND = not determined

## Applications of antibody fragments and antibody fusion proteins

### Applications of antibody fragments in human medicine

#### The smaller the better

Most applications of recombinant antibody fragments are related to diagnosis and therapy in human medicine, which is especially focussed on the use of antibodies as the ideal cancer-targeting reagent (reviewed in [19,60–62]). For some clinical applications small antibody fragments have advantages over whole antibodies. The small size permits them to penetrate tissues and solid tumours more rapidly than whole antibodies [63] which recently also was shown for V<sub>HHs</sub> [64]. Smaller antibody fragments have also a much faster clearance rate in the blood circulation, which leads to differences of selectivity [63]. Nowadays there are also promising pre-clinical and clinical trials with antibody fragments as diagnostic or therapeutic agents [61,65]. Another application of antibody fragments is to treat viral infections with so-called intrabodies, which are intracellular antibodies synthesised by the cell and targeted to inactivate specific proteins within the cell [66].

#### 'Magic bullets' in medicine

The use of bi-functional molecules in medicine is aimed at delivery of a protein drug, which is only active where it is required. It thereby limits the dose of the drug, resulting in less side effects of the drug towards healthy tissue and/or less immunogenic response to the protein drug itself. Also the physical interaction between the target and the effector molecule increases the potency of the effector. Fusion proteins are ideal immuno agents for cancer diagnosis [67] and cancer therapeutics. An example is the use of cancer-specific bi-functional antibodies targeting potent cytotoxic molecules to tumour cells and subsequently eliminate these tumour cells without harming healthy cells [68].

#### Potential applications of V<sub>HHs</sub>

Specific applications of V<sub>HHs</sub> are foreseen in the following direction:

#### V<sub>HHs</sub> as drug carriers

It is expected that V<sub>HHs</sub> are also applicable in diagnosis and therapy in human medicine, especially when an economically feasible production, small size and stability are required (reviewed in [49]). Cortez-Retamozo et al. [64] recently showed that V<sub>HHs</sub> specifically could be targeted to tumour cells, which together with the possibility of generation of bispecific V<sub>HH</sub> constructs [69] is of major interest for cancer therapy.

#### V<sub>HHs</sub> as delivery carriers in the brain

Antibodies and many other water soluble compounds are excluded from the brain by the blood-brain barrier (BBB), thus making treatment of brain-related disease very difficult. Recently, Muruganandam *et al.* [70] showed that V<sub>HH</sub> were able to selectively bind to and transmigrate across the BBB in a human *in vitro* BBB model and partly *in vivo* in mice. This property can be exploited for the development of efficient antibody carriers suitable for delivery of macromolecules across the human BBB and subsequently for treatment of neurological diseases.

#### V<sub>HHs</sub> as potent enzyme inhibitors

Hypervariable regions in V<sub>HHs</sub> are on average longer than those of V<sub>Hs</sub> [71,72]. The extended hypervariable regions of V<sub>HHs</sub> are capable of penetrating deep into the cleft of active sites of enzymes, binding to novel epitopes that are not recognised by conventional antibodies [51,73,74]. Because of this property V<sub>HHs</sub> may act as better potent enzyme inhibitors [51,75,76].

#### V<sub>HHs</sub> in consumer products

Since llama V<sub>HHs</sub> are very stable, even at high temperature, applications can be envisaged in which a high temperature step is involved (e.g. pasteurisation), without losing antigen-binding properties [50]. Recently it was shown that V<sub>HHs</sub> could be used to prevent phage infection in cheese production processes [77], by recognising a structural protein of the phage, which is involved in recognition of the host *Lactococcus lactis*.

**Table 2: Higher eukaryotic expression systems for heterologous protein production and possible advantages and disadvantages of the expression system.**

Expression systems	Ease of molecular cloning	upscaling	Economic feasibility <sup>1</sup>	Pathogenic contaminants <sup>2</sup>	References <sup>3</sup>
Mammalian cells	+	+/-	+	+	[59,150–154]
Insect cells	++	+	+	+	[155–160]
Plants	++	+++	++	++	[92,93,161,162]
Transgenic animals*	+/-	+++	+/-	+/-	[163–166]
Yeasts	+++	+++	+++	+++	See references in section <b>Production of antibody fragments by lower eukaryotes.</b>
Filamentous fungi	+++	+++	+++	+++	[4,123,128]

+++ = excellent, ++ = good, + = sufficient, +/- = poor. \* With transgenic animals in this context is mentioned the production of antibodies or antibody fragments in the milk of transgenic animals, for example rabbits, sheep, goats or cows <sup>1</sup> With economical feasibility is mentioned the time and cost of molecular cloning, upscaling and downstream processing (purification). <sup>2</sup> Pathogenic contaminants like viruses or pyrogens. <sup>3</sup> Articles dealing with production of antibodies, antibody fragments and antibody fusion proteins.

### **Antibody fragments and antibody fusion proteins for large-scale applications and consumer products**

Many additional applications can be envisaged if an inexpensive and simple production system is available, yielding large amounts of antibody fragments that can be purified easily. The highly specific antigen-binding ability could be used for inactivating bacteria or specific enzymes that can cause spoilage of food. Other suggested applications are the use in biosensors, treatment of wastewater [78], industrial scale separation processes such as separation of chiral molecules [79], purification of specific components (proteins) from biological materials or the use as abzymes [80,81]. They have also been considered as components of novel consumer goods with new improved functionalities, in oral care and personal hygiene (*e.g.* in toothpaste or mouthwashes [82]). For dental applications antibody fragments can be coupled to enzymes to increase the concentration of antimicrobials like hypothiocyanate and hypohalites, for example glucose oxidase (GOX; [83]), galactose oxidase (GaOX; [84]) or lactate oxidase (LOX; [85]). Other examples are targeted bleach in laundry washing (*e.g.* detergents containing antibodies coupled to molecules that specifically remove difficult stains) or the use in shampoos where antibodies act to prevent dandruff by inhibiting growth of specific microorganisms causing this [3].

### **Suitable expression systems for the large-scale production of antibody fragments and antibody fusion proteins**

To be able to use antibody fragments and antibody fusion proteins in these large scale applications, a suitable expression system has to be chosen. Several expression systems are available, both from prokaryotic (Table 1) and eukaryotic (Table 2) origin. Our main interest goes out to these systems that are able to economically produce large

amount of proteins into the culture medium. Several of these systems can be considered as suitable (both from prokaryotic and eukaryotic origin). Hereafter several of these systems will be discussed, with an emphasis on yeast and fungal systems.

### **Drawbacks using *E. coli* as a host for antibody fragment production**

As described in the section **Production of recombinant antibody fragments by *Escherichia coli***, this micro-organism has shown to be a potential expression host for antibody fragments and fusion proteins. Although the general production yields in shake-flask cultures are low (several mg/L), in fermentation processes several g/L could be obtained (reviewed in [86]). There are two possibilities of antibody fragment production in *E. coli*, either by secretion of the fragments into the culture medium and/or periplasmic space (the compartment between the inner and outer membrane) or preparation of inclusion bodies with subsequent *in vitro* folding. However, both strategies have disadvantages that make the use of this prokaryote not attractive for the large-scale production of antibody fragments and antibody fusion proteins. Firstly, the secretion of folded and fully assembled fragments in the medium or periplasmic space is often accompanied with cell lysis and subsequent product loss. Secondly, 'toxicity' of the antibody sequence and concomitant plasmid loss is frequently observed, which hamper high production levels (reviewed in [25]). Thirdly, expression of the fragments in inclusion bodies, which often results in insoluble protein aggregates [87], demands laborious and cost-intensive *in vitro* refolding (denaturation and renaturation) and purification steps. Hence, the final yield of fragments is only a small percentage of the protein that was initially present in the inclusion bodies even though purification steps are nowadays facilitated by affinity

chromatography using C-terminal polypeptide tails, like poly-His<sub>6</sub> or FLAG [88,89]. Recently, production of soluble and functional scFv by *E. coli* could be increased by improving disulfide bond formation activity in the cytoplasm, using mutants and overexpression of disulfide-bond isomerase [90]. Finally, *E. coli* is unable to carry out eukaryotic post-translational modifications and is therefore not suitable when glycosylation of antibody fragments or more importantly the fusion proteins is required.

#### Alternative prokaryotic expression systems

*E. coli* is not the only available prokaryotic expression system, although it is rather dominant in the field. Alternative prokaryotic expression systems are available for antibody fragment production (Table 1). However, these will encounter similar limitations as *E. coli*, even though most organisms described in Table 1 secrete the investigated antibody fragment into the culture medium. A field where production of antibody fragments in prokaryotic cells could still be interesting, is in food grade organisms used for delivery passive immunisation in humans, by means of functional foods. In a recent article, Kruger *et al.* [91] reported the production of scFv antibody fragments against *Streptococcus mutans* by the Gram positive food grade bacteria *Lactobacillus zeae*. In experimental animals a decrease of *S. mutans* and reduced development of caries was observed.

#### Eukaryotic expression systems

Also several eukaryotic systems can be envisaged for large-scale production of antibody fragments and antibody fusion proteins (see also [34]), like mammalian cells, insect cells, plants, transgenic animals and lower eukaryotes (see Table 2).

The production of therapeutical whole antibodies is well established in mammalian cells. However, large-scale production is expensive and time-consuming.

'Plantibodies' can be produced in several plant target organs (reviewed in [92]). Roots, storage organs (seeds and tubers) and fruiting bodies can be suitable for mass oral (edible) applications (see [93] and references therein). Expression of scFv in transgenic plants has been proposed as a way to produce and store pharmaceutical antibodies [94,95] and as means to block physiological processes in the plant itself [96] or establish plant pathogen resistance [97]. Plants show several advantages as large-scale antibody production systems, like the ease and low costs of growing plants, even in large quantities. However, the generation of transgenic plants that express antibodies is a time consuming process and the downstream processing to isolate the expressed antibodies from the plant parts is relatively expensive and laborious.

#### Production of antibody fragments by lower eukaryotes

An attractive possibility for the cost-effective large-scale production of antibody fragments and antibody fusion proteins are yeast or fungal fermentations. Large-scale fermentation of these organisms is an established technology already used for bulk production of several other recombinant proteins and extensive knowledge is available on downstream processes. Besides that, yeasts and filamentous fungi are accessible for genetic modifications and the protein of interest may be secreted into the culture medium. In addition, some of their products have the so-called GRAS (Generally Regarded As Safe) status and they do not harbour pyrogens, toxins or viral inclusions.

#### Methylotrophic and other yeasts

The methylotrophic and other yeasts like *Candida boidinii*, *Hansenula polymorpha*, *Pichia methanolica* and *Pichia pastoris* are well known systems for the production of heterologous proteins (reviewed in [98]). High levels of heterologous proteins (milligram-to-gram quantities) can be obtained and scaling up to fermentation for industrial applications is possible [99–101].

Especially the *P. pastoris* system is used in several industrial-scale production processes [102]. Ridder *et al.* [103] were the first to report the expression of a scFv fragment by *P. pastoris*. From then on several papers reported about the use of *P. pastoris* for the production of recombinant antibodies and fragments thereof [104,105]. In shake-flask cultures a level of 250 mg/L scFv was obtained [106] and Freyre *et al.* [107] were able to obtain even an expression level of 1.2 g/L scFv fragment under fermentation conditions. However, Cupit *et al.* [108] also showed that the production of antibody fragments by *P. pastoris* is not always a success story.

Based on the described results the commercial recombinant antibody production by *P. pastoris* is promising. However, products currently obtained from *P. pastoris* are not regarded as GRAS, which may limit its use.

Wood *et al.* [109] were the first to report the production of mouse IgM by the baker's yeast *S. cerevisiae*, although only unassembled chains were detected in the culture medium. However, the production of Fab fragments was possible as was first shown by Horwitz *et al.* [110]. Although the obtained levels were low, functional Fab fragments were secreted in the culture medium. Davis *et al.* [111] expressed scFv antibody fragments in *Schizosaccharomyces pombe*. Studies on the scFv production in the non conventional yeasts *Yarrowia lipolytica* and *Kluyveromyces lactis* resulted in 10–20 mg/L functional and soluble anti-Ras scFv [112].



**Filamentous fungi:** *Trichoderma reesei* and *Aspergillus* spp  
 Filamentous fungi, in particular species from the genera *Trichoderma* and *Aspergillus* have the capacity to secrete large amounts of proteins, metabolites and organic acids into their culture medium. This property has been widely exploited by the food and beverage industries where compounds secreted by these filamentous fungal species have been used for decades. This has led to the GRAS status for some of their products. Filamentous fungi like *A. awamori*, *A. niger* and *A. oryzae* are therefore suitable organisms for the production of commercially interesting homologous and heterologous proteins [113–115]. Strategies to improve protein secretion by filamentous fungi are extensively reviewed in [116–119].

Production strains of *Trichoderma reesei* (*Hypocrea jecorina*) have an exceptional secretion capacity up to 35 g protein/L, where half of the secreted protein consists of the cellulase cellobiohydrolase I (CBH1; [120]). Therefore, *Trichoderma* is considered as an excellent host for the production of heterologous proteins (reviewed in [121,122]). Nyssönen *et al.* [123] reported a production of 1 mg/L in shake-flasks of Fab antibody fragments by *T. reesei* Rut-C30. More strikingly, when the Fab antibody fragment chain was fused to the core-linker region of CBH1, a production level of 40 mg/L in shake-flasks and 150 mg/L in bioreactor cultivations was obtained [123,124].

### The use of *S. cerevisiae* and *A. awamori* for the large-scale production of antibody fragments and fusion proteins

In our own laboratory at TNO Nutrition and Food Research in Zeist (The Netherlands) and in collaboration with Unilever Research Vlaardingen (The Netherlands) research on antibody fragment production in *S. cerevisiae* and *A. awamori* has been carried out [125,126]. The aim of this project was a detailed comparison of both expression systems, in relation to their possible large-scale production process of antibody fragments and fusion proteins. In the framework of this collaboration also a new *A. awamori* expression system, based on xylose induction was developed [127].

### The use of *S. cerevisiae* and *A. awamori* for the large-scale production of scFv

To investigate the feasibility of a large-scale cost-effective process for the extracellular production of (functionalised) scFv fragments initially *S. cerevisiae* was used. However, it was shown that *S. cerevisiae* was a poor host for the production of scFv, since the secretion of scFv was hampered by improper folding of the fragments, because large aggregates were formed in the ER and vacuolar-like organelles. It was hypothesised that the exposure of the hydrophobic surfaces on the V<sub>L</sub> and V<sub>H</sub> chains of scFv plays

an important role in the accumulation of scFv in the cell [128]. Shusta *et al.* [129] reported the increase of scFv production up to 20 mg/L in *S. cerevisiae* by optimising the expression system by overexpression of two ER resident chaperones and reduction of growth temperature. Kauffman *et al.* [130] showed that overexpression of scFv in *S. cerevisiae* resulted in cellular stress, displayed by decreased growth rates and induction of the Unfolded Protein Response (UPR). It was hypothesised that a functional UPR was required to decrease the malformed scFv in the ER, leading to a recovery from cell stress.

As further improved levels were desired also a fungal expression system was considered [4]. In shake-flask cultures a production level of 10 mg/L was achieved by using *A. awamori* as production host. As secretion of a heterologous protein can be greatly enhanced by fusing it to a "carrier" protein such as glucoamylase (GLA; [117,118]), also this fusion-approach was employed. Analysis of the culture medium of transformants carrying the fusion construct revealed a production of approximately 50 mg/L scFv in the culture medium [4]. Several commercially interesting scFv fragments were investigated for their ability to be produced by *A. awamori* using the GLA-fusion strategy. The results showed that the production levels differed significantly between the different scFv transformants. Interestingly, in some cases increased levels of scFv detected in the culture medium corresponded to an increase of transcription level of the ER chaperone BiPA [131], indicating that the antibody fragments, like in *S. cerevisiae*, may have problems with correct folding and aggregate in the fungal cell.

To increase production levels, successful 10 L and 1,5 × 10<sup>4</sup> L scale fermentations were carried out resulting in 200 mg/L scFv under optimal conditions. However, variable amounts of scFv dimers and other multimers were observed. Recent fermentation experiments performed by Sotiriadis *et al.* [132] showed that the highest scFv level was observed when induction was started in the late exponential phase. An increase of the carbon and nitrogen source concentrations and a decreased of the concentration of the inducer, resulted in increased product yields.

### Production of Llama V<sub>HH</sub> antibody fragments by *S. cerevisiae* and *A. awamori*

Although the production of scFv fragments by *S. cerevisiae* and *A. awamori* was successful, levels up to several g/L were not achieved. Possibly the hydrophobic regions of the scFv, responsible for keeping the variable regions of the heavy and light chains together, could also interact with other molecules in the cell. Aggregation of scFv in *S. cerevisiae* may result in accumulation and subsequent degradation (of a part) of the antibody fragment molecules [128] as frequently observed when expressing heterolo-

gous proteins that exhibit hydrophobic surfaces [133]. Interestingly, antibody fragments devoid of these hydrophobic surfaces could be obtained from camels, dromedaries and llamas ( $V_{HH}$ s, see **Llama Heavy-chain antibody fragments ( $V_{HH}$ s)** and [13]), providing an option to improve production levels in relevant microorganisms [126].

$V_{HH}$ s could be produced in *E. coli* up to levels of 6 mg/L, were found to be extremely stable, highly soluble and reacted specifically and with high affinity with antigens [52].  $V_{HH}$ s were produced in *S. cerevisiae* at levels over 100 mg/L in shake-flask cultures [134], although considerable amounts of  $V_{HH}$ s were detected intracellularly. From a  $1.5 \times 10^4$  L fed-batch fermentation, 1.3 kg of  $V_{HH}$ s was obtained, which clearly showed that these fragments could be produced in this host more efficiently than scFv fragments [135]. For a cost-effective large-scale process for the production of  $V_{HH}$ s in *S. cerevisiae* further improvement is required. Van der Linden *et al.* [54] showed that production of  $V_{HH}$ s by *S. cerevisiae* could be improved by DNA shuffling techniques, in which three homologous  $V_{HH}$  genes were randomly fragmented and reassembled subsequently.

Based on the fact that *A. awamori* performed superior for scFv also the possibility of  $V_{HH}$  production by *A. awamori* was investigated. As a model  $V_{HH}$ s against the hapten RR6 were chosen [134]. Gene fragments coding for anti-RR6  $V_{HH}$ s were cloned in an expression vector containing the highly inducible endoxylanase promoter. Recent experiments (Joosten *et al.* submitted) showed that functional  $V_{HH}$ s could be produced in the culture medium in shake-flask cultures, albeit at relatively low levels. For further optimisation a carrier strategy and controlled fermentations will be carried out.

#### **Production of 'Magic bullets' by *A. awamori***

A major research interest is the production of fusion proteins or 'Magic bullets', consisting of an antibody fragment (scFv or  $V_{HH}$  fragment) fused to an enzyme of interest. In our laboratory research has been carried out with a few examples of scFv fragments coupled to glucose oxidase (GOX). GOX is already for many years an interesting enzyme for coupling to antibodies for killing cells [136]. A scFv, which recognises for example oral *Streptomyces*, when fused to GOX, which is an antimicrobial enzyme, may kill bacteria by generation of the bactericidal hydrogen peroxide. In activity assays it was shown that the fusion protein produced by *A. awamori* was functional, both in binding to the antigen and GOX activity [4].

In the detergent industry enzymatic bleaching may be a good alternative to the current chemical bleaching used. To make these laundry-cleaning products more effective,

the production of Magic bullets by filamentous fungi or yeasts is of interest. An enzyme coupled to an antibody fragment recognising persistent stains from e.g. azo-dyes [134] results in a more directed bleaching process, resulting in lower amounts of required detergent, reduction of harmful effects of the enzyme to the textile and lower environmental burden (see Figure 3).


Currently we are investigating the feasibility of production of  $V_{HH}$ -enzyme fusions by *A. awamori*. One of the  $V_{HH}$ s used is a model llama  $V_{HH}$ , recognising the azo-dye Reactive Red 6 (RR6 [134]). As a bleaching enzyme, the *Arthromyces ramosus* peroxidase (ARP) [137,138] was genetically linked to the  $V_{HH}$  fragment. This peroxidase utilises hydrogen peroxide to catalyse the oxidation of a wide range of organic and inorganic compounds, which makes the enzyme suitable for use in bleaching processes [139]. ARP alone could be produced in high amounts by *A. awamori* (800 mg/L; Lokman *et al.* submitted). Preliminary results showed the feasibility of fusion protein production by *A. awamori*, yielding high levels of ARP- $V_{HH}$  fusion protein in controlled fermentation experiments (Joosten *et al.* manuscript in preparation). The fusion protein showed both ARP activity and azo-dye binding activity.

In future experiments  $V_{HH}$ s fragments can be replaced by other more relevant antibody fragments, for example those binding tomato or blood spots. Also the peroxidase part of the fusion can be further optimised.

#### **Conclusions and future prospects**

Recent developments in the fields of antibody engineering and expression systems have enabled the engineering and production of antibodies and antibody fragments for a wide variety of applications. A lot of examples are already mentioned, but presumably more applications can be envisaged. The development of the 'Magic bullet' approach will even increase the interest in antibodies and their related products, also for applications in human medicine. A recently envisioned application that is of much interest, is the use of antibody fragments in micro-arrays. Antibody arrays can be used for proteomic analysis by comparing the differences in presence of proteins in healthy and diseased cells. For this purpose antibody fragments derived from large phage-antibody libraries can be used as probes to capture proteins on chips in a high-throughput system (reviewed in [140,141]). In this respect,  $V_{HH}$ s fragments are of great interest, due to their simple and stable structure.

In this review we evaluated whether the yeast *S. cerevisiae* and the filamentous fungus *A. awamori* are suitable expression systems for the large-scale production of antibody fragments and antibody fusion proteins. Although



**Figure 3**

Schematic example of the 'Magic bullet' approach in consumer applications, where an antibody fragment (in this case a llama variable heavy-chain antibody fragment;  $V_{HH}$ ) recognising a spot on textile, is coupled to an effector molecule (in this case *A. ramosus* peroxidase; ARP). ARP is a peroxidase, which utilises hydrogen peroxide to catalyse the oxidation of a wide range of organic and inorganic compounds, which makes the enzyme suitable for use in bleaching processes [139].

*A. awamori* is not the best expression system for the production single antibody domains (scFv and  $V_{HH}$  fragments), in particular for the production of antibody fusion proteins filamentous fungi offer significant potential. In particular in those cases where specific post-translational modification (*e.g.* N-glycosylation) is required for functional expression of the effector protein (also in relation to pharmaceutical applications). In contrast to *S. cerevisiae*, filamentous fungi do not show extensive hyperglycosylation [142].

Both the scFv-GOX as well as results from ARP- $V_{HH}$  fusion proteins showed that the filamentous fungal system is a promising candidate for the production of antibody fusion proteins. In the future production of other fusion proteins can be investigated in this or other fungal expression systems, allowing a potential breakthrough for antibody technology in producing large amounts of specific recognition units coupled to effector molecules for consumer applications.

#### Acknowledgements

The authors would like to thank Theo Verrips and Nicole van Luijk for critical reading of this manuscript.

## References

- Köhler G and Milstein C **Continuous cultures of fused cells secreting antibody of predefined specificity.** *Nature* 1975, **256**:495-497
- Porter P, Coley J and Gani M **Immunochemical criteria for successful matching of monoclonal antibodies to immunoassays of peptide hormones for assessment of pregnancy and ovulation.** *Prog Clin Biol Res* 1988, **285**:181-200
- Van der Linden RHJ **Unique characteristics of llama heavy chain antibodies.** Ph.D. thesis Utrecht University. Utrecht (The Netherlands) 1999,
- Frenken LG, Hessing JG, Van den Hondel CA and Verrrips CT **Recent advances in the large-scale production of antibody fragments using lower eukaryotic microorganisms.** *Res Immunol* 1998, **149**:589-599
- Winter G, Griffiths AD, Hawkins RE and Hoogenboom HR **Making antibodies by phage display technology.** *Annu Rev Immunol* 1994, **12**:433-455
- Winter G and Milstein C **Man-made antibodies.** *Nature* 1991, **349**:293-299
- Padlan EA **Anatomy of the antibody molecule.** *Mol Immunol* 1994, **31**:169-217
- Better M, Chang CP, Robinson RR and Horwitz AH **Escherichia coli secretion of an active chimeric antibody fragment.** *Science* 1988, **240**:1041-1043
- Skerra A and Pluckthun A **Assembly of a functional immunoglobulin F<sub>v</sub> fragment in Escherichia coli.** *Science* 1988, **240**:1038-1041
- Cai X and Garen A **A melanoma-specific V<sub>H</sub> antibody cloned from a fusion phage library of a vaccinated melanoma patient.** *Proc Natl Acad Sci U S A* 1996, **93**:6280-6285
- Ward ES, Gussow D, Griffiths AD, Jones PT and Winter G **Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli.** *Nature* 1989, **341**:544-546
- Borrebaeck CA, Malmborg AC, Furebring C, Michaelsson A, Ward S, Danielsson L and Ohlin M **Kinetic analysis of recombinant antibody-antigen interactions: relation between structural domains and antigen binding.** *Biotechnology (N Y)* 1992, **10**:697-698
- Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N and Hamers R **Naturally occurring antibodies devoid of light chains.** *Nature* 1993, **363**:446-448
- Muyldermans S and Lauwereys M **Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies.** *J Mol Recognit* 1999, **12**:131-140
- Nguyen VK, Hamers R, Wyns L and Muyldermans S **Loss of splice consensus signal is responsible for the removal of the entire C<sub>H1</sub> domain of the functional camel IgG2A heavy-chain antibodies.** *Mol Immunol* 1999, **36**:515-524
- Woolven BP, Frenken LG, van der Logt P and Nicholls PJ **The structure of the llama heavy chain constant genes reveals a mechanism for heavy-chain antibody formation.** *Immunogenetics* 1999, **50**:98-101
- Nguyen VK, Desmyter A and Muyldermans S **Functional heavy-chain antibodies in Camelidae.** *Adv Immunol* 2001, **79**:261-296
- Nguyen VK, Su C, Muyldermans S and van der Loo W **Heavy-chain antibodies in Camelidae; a case of evolutionary innovation.** *Immunogenetics* 2002, **54**:39-47
- Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A and Batra SK **Pharmacokinetics and biodistribution of genetically-engineered antibodies.** *Q J Nucl Med* 1998, **42**:225-241
- Kipriyanov SM and Little M **Generation of recombinant antibodies.** *Mol Biotechnol* 1999, **12**:173-201
- Neuberger MS, Williams GT, Mitchell EB, Jouhal SS, Flanagan JG and Rabbitts TH **A hapten-specific chimaeric IgE antibody with human physiological effector function.** *Nature* 1985, **314**:268-270
- Riechmann L, Clark M, Waldmann H and Winter G **Reshaping human antibodies for therapy.** *Nature* 1988, **332**:323-327
- Holliger P and Hoogenboom H **Antibodies come back from the brink.** *Nat Biotechnol* 1998, **16**:1015-1016
- Gura T **Therapeutic antibodies: magic bullets hit the target.** *Nature* 2002, **417**:584-586
- Pluckthun A **Escherichia coli producing recombinant antibodies.** *Bioprocess Technol* 1994, **19**:233-252
- Le Gall F, Bove JM and Garnier M **Engineering of a single-chain variable-fragment (scFv) antibody specific for the stolbur phytoplasma (Mollicute) and its expression in Escherichia coli and tobacco plants.** *Appl Environ Microbiol* 1998, **64**:4566-4572
- Zhu Z, Zapata G, Shalaby R, Snedecor B, Chen H and Carter P **High level secretion of a humanized bispecific diabody from Escherichia coli.** *Biotechnology (N Y)* 1996, **14**:192-196
- McCafferty J, Griffiths AD, Winter G and Chiswell DJ **Phage antibodies: filamentous phage displaying antibody variable domains.** *Nature* 1990, **348**:552-554
- Hoogenboom HR and Chames P **Natural and designer binding sites made by phage display technology.** *Immunol Today* 2000, **21**:371-378
- Hoogenboom HR, de Bruine AP, Hufton SE, Hoet RM, Arends JW and Roovers RC **Antibody phage display technology and its applications.** *Immunotechnology* 1998, **4**:1-20
- Marks JD, Griffiths AD, Malmqvist M, Clackson TP, Bye JM and Winter G **By-passing immunization: building high affinity human antibodies by chain shuffling.** *Biotechnology (N Y)* 1992, **10**:779-783
- Worn A and Pluckthun A **Stability engineering of antibody single-chain F<sub>v</sub> fragments.** *J Mol Biol* 2001, **305**:989-1010
- Raag R and Whitlow M **Single-chain F<sub>v</sub> s.** *FASEB J* 1995, **9**:73-80
- Verma R, Boleti E and George AJ **Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems.** *J Immunol Methods* 1998, **216**:165-181
- Huston JS, McCartney J, Tai MS, Mottola-Hartshorn C, Jin D, Warren F, Keck P and Oppermann H **Medical applications of single-chain antibodies.** *Int Rev Immunol* 1993, **10**:195-217
- Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS and Whitlow M **Single-chain antigen-binding proteins.** *Science* 1988, **242**:423-426
- Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, Margolies MN, Ridge RJ, Brucoleri RE, Haber E and Crea R **Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain F<sub>v</sub> analogue produced in Escherichia coli.** *Proc Natl Acad Sci U S A* 1988, **85**:5879-5883
- Glockshuber R, Malia M, Pfitzinger I and Pluckthun A **A comparison of strategies to stabilize immunoglobulin F<sub>v</sub>-fragments.** *Biochemistry* 1990, **29**:1362-1367
- Mallender WD, Carrero J and Voss EW Jr **Comparative properties of the single chain antibody and F<sub>v</sub> derivatives of mAb 4-4-20. Relationship between interdomain interactions and the high affinity for fluorescein ligand.** *J Biol Chem* 1996, **271**:5338-5346
- Whitlow M, Bell BA, Feng SL, Filpula D, Hardman KD, Hubert SL, Rolence ML, Wood JF, Schott ME and Milenic DE **An improved linker for single-chain F<sub>v</sub> with reduced aggregation and enhanced proteolytic stability.** *Protein Eng* 1993, **6**:989-995
- Brinkmann U, Reiter Y, Jung SH, Lee B and Pastan I **A recombinant immunotoxin containing a disulfide-stabilized F<sub>v</sub> fragment.** *Proc Natl Acad Sci U S A* 1993, **90**:7538-7542
- Reiter Y, Brinkmann U, Kreitman RJ, Jung SH, Lee B and Pastan I **Stabilization of the F<sub>v</sub> fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions.** *Biochemistry* 1994, **33**:5451-5459
- Reiter Y, Brinkmann U, Lee B and Pastan I **Engineering antibody F<sub>v</sub> fragments for cancer detection and therapy: disulfide-stabilized F<sub>v</sub> fragments.** *Nat Biotechnol* 1996, **14**:1239-1245
- Atwell JL, Breheny KA, Lawrence LJ, McCoy AJ, Kortt AA and Hudson PJ **scFv multimers of the anti-neuraminidase antibody Nc10: length of the linker between V<sub>H</sub> and V<sub>L</sub> domains dictates precisely the transition between diabodies and triabodies.** *Protein Eng* 1999, **12**:597-604
- Hudson PJ and Kortt AA **High avidity scFv multimers; diabodies and triabodies.** *J Immunol Methods* 1999, **231**:177-189
- Cao Y and Suresh MR **Bispecific antibodies as novel bioconjugates.** *Bioconjug Chem* 1998, **9**:635-644
- Kriangkum J, Xu B, Nagata LP, Fulton RE and Suresh MR **Bispecific and bifunctional single chain recombinant antibodies.** *Biomol Eng* 2001, **18**:31-40
- Sheriff S and Constantine KL **Redefining the minimal antigen-binding fragment.** *Nat Struct Biol* 1996, **3**:733-736
- Muyldermans S **Single domain camel antibodies: current status.** *J Biotechnol* 2001, **74**:277-302

50. van der Linden RH, Frenken LG, de Geus B, Harmsen MM, Ruuls RC, Stok W, de Ron L, Wilson S, Davis P and Verrips CT **Comparison of physical chemical properties of llama V<sub>HH</sub> antibody fragments and mouse monoclonal antibodies.** *Biochim Biophys Acta* 1999, **1431**:37-46
51. Lauwereys M, Arbabi Ghahroudi M, Desmyter A, Kinne J, Holzer W, De Genst E, Wyns L and Muyldermans S **Potent enzyme inhibitors derived from dromedary heavy-chain antibodies.** *Embo J* 1998, **17**:3512-3520
52. Ghahroudi M, Desmyter A, Wyns L, Hamers R and Muyldermans S **Selection and identification of single domain antibody fragments from camel heavy-chain antibodies.** *FEBS Lett* 1997, **414**:521-526
53. Knarr G, Gething MJ, Modrow S and Buchner J **BiP binding sequences in antibodies.** *J Biol Chem* 1995, **270**:27589-27594
54. van der Linden RH, de Geus B, Frenken GJ, Peters H and Verrips CT **Improved production and function of llama heavy chain antibody fragments by molecular evolution.** *J Biotechnol* 2000, **80**:261-270
55. Davies J and Riechmann L **'Camelising' human antibody fragments: NMR studies on V<sub>H</sub> domains.** *FEBS Lett* 1994, **339**:285-290
56. Davies J and Riechmann L **Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human V<sub>H</sub> domains with improved protein stability.** *Protein Eng* 1996, **9**:531-537
57. Tanha J, Xu P, Chen Z, Ni F, Kaplan H, Narang SA and MacKenzie CR **Optimal design features of camelized human single-domain antibody libraries.** *J Biol Chem* 2001, **276**:24774-24780
58. Riechmann L and Muyldermans S **Single domain antibodies: comparison of camel V<sub>H</sub> and camelised human V<sub>H</sub> domains.** *J Immunol Methods* 1999, **231**:25-38
59. Neuberger MS, Williams GT and Fox RO **Recombinant antibodies possessing novel effector functions.** *Nature* 1984, **312**:604-608
60. Hazra DK, Britton KE, Lahiri VL, Gupta AK, Khanna P and Saran S **Immunotechnological trends in radioimmunotargeting: from 'Magic bullet' to 'smart bomb'.** *Nucl Med Commun* 1995, **16**:66-75
61. Hudson PJ **Recombinant antibody constructs in cancer therapy.** *Curr Opin Immunol* 1999, **11**:548-557
62. von Mehren M and Weiner LM **Monoclonal antibody-based therapy.** *Curr Opin Oncol* 1996, **8**:493-498
63. Yokota T, Milenic DE, Whitlow M and Schlom J **Rapid tumor penetration of a single-chain F<sub>v</sub> and comparison with other immunoglobulin forms.** *Cancer Res* 1992, **52**:3402-3408
64. Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh G, Gobert M, Conrath K, Muyldermans S, De Baetselier P and Revets H **Efficient tumor targeting by single-domain antibody fragments of camels.** *Int J Cancer* 2002, **98**:456-462
65. Maynard JA, Maassen CB, Leppla SH, Brasky K, Patterson JL, Iverson BL and Georgiou G **Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity.** *Nat Biotechnol* 2002, **20**:597-601
66. Marasco WA **Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy.** *Immunotechnology* 1995, **1**:1-19
67. Spooner RA, Murray S, Rowlinson-Busza G, Deonarain MP, Chu A and Epenetos AA **Genetically engineered antibodies for diagnostic pathology.** *Hum Pathol* 1994, **25**:606-614
68. Boleti E, Deonarain MP, Spooner RA, Smith AJ, Epenetos AA and George AJ **Construction, expression and characterisation of a single chain anti-tumour antibody (scFv)-IL-2 fusion protein.** *Ann Oncol* 1995, **6**:945-947
69. Conrath K, Lauwereys M, Wyns L and Muyldermans S **Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs.** *J Biol Chem* 2001, **276**:7346-7350
70. Muruganandam A, Tanha J, Narang S and Stanimirovic D **Selection of phage-displayed llama single-domain antibodies that transigrate across human blood-brain barrier endothelium.** *Faseb J* 2002, **16**:240-242
71. Vu KB, Ghahroudi MA, Wyns L and Muyldermans S **Comparison of llama VH sequences from conventional and heavy chain antibodies.** *Mol Immunol* 1997, **34**:1121-1131
72. Harmsen MM, Ruuls RC, Nijman IJ, Niewold TA, Frenken LG and de Geus B **Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features.** *Mol Immunol* 2000, **37**:579-590
73. Desmyter A, Transue TR, Ghahroudi MA, Thi MH, Poortmans F, Hamers R, Muyldermans S and Wyns L **Crystal structure of a camel single-domain V<sub>H</sub> antibody fragment in complex with lysozyme.** *Nat Struct Biol* 1996, **3**:803-811
74. Transue TR, De Genst E, Ghahroudi MA, Wyns L and Muyldermans S **Camel single-domain antibody inhibits enzyme by mimicking carbohydrate substrate.** *Proteins* 1998, **32**:515-522
75. Conrath KE, Lauwereys M, Galleni M, Matagne A, Frere JM, Kinne J, Wyns L and Muyldermans S **Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the Camelidae.** *Antimicrob Agents Chemother* 2001, **45**:2807-2812
76. Desmyter A, Spinelli S, Payan F, Lauwereys M, Wyns L, Muyldermans S and Cambillau C **Three camelid V<sub>HH</sub> domains in complex with porcine pancreatic alpha-amylase. Inhibition and versatility of binding topology.** *J Biol Chem* 2002, **277**:23645-23650
77. Ledeboer AM, Bezemer S, de Hiaard JJ, Schaffers IM, Verrips CT, van Vliet C, Dusterhoft EM, Zoon P, Moineau S and Frenken LG **Preventing phage lysis of *Lactococcus lactis* in cheese production using a neutralizing heavy-chain antibody fragment from llama.** *J Dairy Sci* 2002, **85**:1376-1382
78. Graham BM, Porter AJ and Harris WJ **Cloning, expression and characterization of a single-chain antibody fragment to the herbicide paraquat.** *J Chem Technol Biotechnol* 1995, **63**:279-289
79. Got PA and Scherrmann JM **Stereoselectivity of antibodies for the bioanalysis of chiral drugs.** *Pharm Res* 1997, **14**:1516-1523
80. Janda KD, Lo LC, Lo CH, Sim MM, Wang R, Wong CH and Lerner RA **Chemical selection for catalysis in combinatorial antibody libraries.** *Science* 1997, **275**:945-948
81. Wade H and Scanlan TS **The structural and functional basis of antibody catalysis.** *Annu Rev Biophys Biomol Struct* 1997, **26**:461-493
82. Beggs T, Hammond K and Klugkist J **Oral compositions.** *WO 95/01155* 1995,
83. Hill KJ, Kaszuba M, Creeth JE and Jones MN **Reactive liposomes encapsulating a glucose oxidase-peroxidase system with antibacterial activity.** *Biochim Biophys Acta* 1997, **1326**:37-46
84. Lis M and Kuramitsu HK **Galactose oxidase-glycan binding domain fusion proteins as targeting inhibitors of dental plaque bacteria.** *Antimicrob Agents Chemother* 1997, **41**:999-1003
85. Hayes ML **A lactate peroxidase salivary peroxidase thiocyanate antibacterial enzyme system.** *Microb Ecol Health Dis* 1996, **9**:321-328
86. Harrison JS and Keshavarz-Moore E **Production of antibody fragments in *Escherichia coli*.** *Ann N Y Acad Sci* 1996, **782**:143-158
87. Skerra A **Bacterial expression of immunoglobulin fragments.** *Curr Opin Immunol* 1993, **5**:256-262
88. Kortt AA, Malby RL, Caldwell JB, Gruen LC, Ivancic N, Lawrence MC, Howlett GJ, Webster RG, Hudson PJ and Colman PM **Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex.** *Eur J Biochem* 1994, **221**:151-157
89. Casey JL, Keep PA, Chester KA, Robson L, Hawkins RE and Begent RH **Purification of bacterially expressed single chain F<sub>v</sub> antibodies for clinical applications using metal chelate chromatography.** *J Immunol Methods* 1995, **179**:105-116
90. Jurado P, Ritz D, Beckwith J, de Lorenzo V and Fernandez LA **Production of functional single-chain Fv antibodies in the cytoplasm of *Escherichia coli*.** *J Mol Biol* 2002, **320**:1-10
91. Kruger C, Hu Y, Pan Q, Marcotte H, Hultberg A, Delwar D, Van Dalen PJ, Pouwels PH, Leer RJ, Kelly CG, Van Dollenweerd C, Ma JK and Hammarstrom L **In situ delivery of passive immunity by *lactobacilli* producing single-chain antibodies.** *Nat Biotechnol* 2002, **20**:702-706
92. Conrad U and Fiedler U **Compartment-specific accumulation of recombinant immunoglobulins in plant cells: an essential tool for antibody production and immunomodulation of physiological functions and pathogen activity.** *Plant Mol Biol* 1998, **38**:101-109
93. Peeters K, De Wilde C, De Jaeger G, Angenon G and Depicker A **Production of antibodies and antibody fragments in plants.** *Vaccine* 2001, **19**:2756-2761
94. Stöger E, Vaquero C, Torres E, Sack M, Nicholson L, Drossard J, Williams S, Keen D, Perrin Y, Christou P and Fischer R **Cereal crops as**

- viable production and storage systems for pharmaceutical scFv antibodies. *Plant Mol Biol* 2000, **42**:583-590
95. Yuan Q, Hu W, Pestka JJ, He SY and Hart LP **Expression of a functional antizerealone single-chain F<sub>v</sub> antibody in transgenic *Arabidopsis* plants.** *Appl Environ Microbiol* 2000, **66**:3499-3505
  96. De Jaeger G, De Wilde C, Eeckhout D, Fiers E and Depicker A **The plantibody approach: expression of antibody genes in plants to modulate plant metabolism or to obtain pathogen resistance.** *Plant Mol Biol* 2000, **43**:419-428
  97. Ziegler A and Torrance L **Applications of recombinant antibodies in plant pathology.** *Mol Plant Pathol* 2002, **3**:401-407
  98. Gellissen G **Heterologous protein production in methylotrophic yeasts.** *Appl Microbiol Biotechnol* 2000, **54**:741-750
  99. Cregg JM, Vedvick TS and Raschke WC **Recent advances in the expression of foreign genes in *Pichia pastoris*.** *Biotechnology (N Y)* 1993, **11**:905-910
  100. Faber KN, Harder W, Ab G and Veenhuis M **Review: methylotrophic yeasts as factories for the production of foreign proteins.** *Yeast* 1995, **11**:1331-1344
  101. Fischer R, Drossard J, Emans N, Commandeur U and Hellwig S **Towards molecular farming in the future: *Pichia pastoris*-based production of single-chain antibody fragments.** *Biotechnol Appl Biochem* 1999, **30**:117-120
  102. Cregg JM, Cereghino JL, Shi J and Higgins DR **Recombinant protein expression in *Pichia pastoris*.** *Mol Biotechnol* 2000, **16**:23-52
  103. Ridder R, Schmitz R, Legay F and Gram H **Generation of rabbit monoclonal antibody fragments from a combinatorial phage display library and their production in the yeast *Pichia pastoris*.** *Biotechnology (N Y)* 1995, **13**:255-260
  104. Andrade EV, Albuquerque FC, Moraes LM, Brigido MM and Santos-Silva MA **Single-Chain F<sub>v</sub> with F<sub>c</sub> Fragment of the Human IgG1 Tag: Construction, *Pichia pastoris* Expression and Antigen Binding Characterization.** *J Biochem (Tokyo)* 2000, **128**:891-895
  105. Pennell CA and Eldin P **In vitro production of recombinant antibody fragments in *Pichia pastoris*.** *Res Immunol* 1998, **149**:599-603
  106. Eldin P, Pauza ME, Hieda Y, Lin G, Murtaugh MP, Pentel PR and Pennell CA **High-level secretion of two antibody single chain F<sub>v</sub> fragments by *Pichia pastoris*.** *J Immunol Methods* 1997, **201**:67-75
  107. Freyre FM, Vazquez JE, Ayala M, Canaan-Haden L, Bell H, Rodriguez I, Gonzalez A, Cintado A and Gavilondo JV **Very high expression of an anti-carcinoembryonic antigen single chain F<sub>v</sub> antibody fragment in the yeast *Pichia pastoris*.** *J Biotechnol* 2000, **76**:157-163
  108. Cupit PM, Whyte JA, Porter AJ, Browne MJ, Holmes SD, Harris WJ and Cunningham C **Cloning and expression of single chain antibody fragments in *Escherichia coli* and *Pichia pastoris*.** *Lett Appl Microbiol* 1999, **29**:273-277
  109. Wood CR, Boss MA, Kenten JH, Calvert JE, Roberts NA and Emtage JS **The synthesis and in vivo assembly of functional antibodies in yeast.** *Nature* 1985, **314**:446-449
  110. Horwitz AH, Chang CP, Better M, Hellstrom KE and Robinson RR **Secretion of functional antibody and Fab fragment from yeast cells.** *Proc Natl Acad Sci U S A* 1988, **85**:8678-8682
  111. Davis GT, Bedzyk WD, Voss EW and Jacobs TW **Single chain antibody (SCA) encoding genes: one-step construction and expression in eukaryotic cells.** *Biotechnology (N Y)* 1991, **9**:165-169
  112. Swennen D, Paul MF, Vernis L, Beckerich JM, Fournier A and Gaillardin C **Secretion of active anti-Ras single-chain Fv antibody by the yeasts *Yarrowia lipolytica* and *Kluyveromyces lactis*.** *Microbiology* 2002, **148**:41-50
  113. Radzio R and Kuck U **Synthesis of biotechnologically relevant heterologous proteins in filamentous fungi.** *Process-biochem* 1997, **32**:529-539
  114. Punt PJ, van Biezen N, Conesa A, Albers A, Mangnus J and van den Hondel C **Filamentous fungi as cell factories for heterologous protein production.** *Trends Biotechnol* 2002, **20**:200-206
  115. van den Hondel CAJMJ, Punt PJ and van Gorcum RFM **Heterologous gene expression in filamentous fungi.** In: *More genetic manipulations of filamentous fungi* (Edited by: Bennet JW, Lasure LL) Orlando, Academic Press 1991, 396-428
  116. Verdoes JC, Punt PJ and van den Hondel CAMJJ **Molecular genetic strain improvement for the overproduction of fungal proteins by filamentous fungi.** *Appl Microbiol Biotechnol* 1995, **43**:195-205
  117. Gouka RJ, Punt PJ and van den Hondel CAMJJ **Efficient production of secreted proteins by *Aspergillus*: progress, limitations and prospects.** *Appl Microbiol Biotechnol* 1997, **47**:1-11
  118. Ward M, Wilson LJ, Kodama KH, Rey MW and Berka RM **Improved production of chymosin in *Aspergillus* by expression as a glucoamylase-chymosin fusion.** *Biotechnology (N Y)* 1990, **8**:435-440
  119. Archer DB, Jeenes DJ and Mackenzie DA **Strategies for improving heterologous protein production from filamentous fungi.** *Antonie Van Leeuwenhoek* 1994, **65**:245-250
  120. Durand H, Clanet M and Tiraby G **Genetic improvement of *Trichoderma reesei* for large scale cellulase production.** *Enzyme Microb Technol* 1988, **6**:341-346
  121. Keranen S and Penttila M **Production of recombinant proteins in the filamentous fungus *Trichoderma reesei*.** *Curr Opin Biotechnol* 1995, **6**:534-537
  122. Nevalainen H, Suominen P and Taimisto K **On the safety of *Trichoderma reesei*.** *J Biotechnol* 1994, **37**:193-200
  123. Nyyssönen E, Penttila M, Harkki A, Saloheimo A, Knowles JK and Keranen S **Efficient production of antibody fragments by the filamentous fungus *Trichoderma reesei*.** *Biotechnology (N Y)* 1993, **11**:591-595
  124. Nyyssönen E, Keranen K, Penttila M, Takkinen K and Knowles JKC **Immunoglobulin production by *Trichoderma*.** *World Patent Application WO 92/01797* 1992,
  125. Hessing JGM, van Gorcum RFM, Verbakel JMA, Musters W, Frenken LGJ, van den Hondel CAMJJ and Verrips CT **Process for producing fusion proteins comprising scFv fragments by a transformed mould.** *World Patent Application WO 94/29457* 1994,
  126. Hamers R, Hamers-Casterman C, Muyldermans S, Frenken LGJ and Verrips CT **Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of *Camelidae*.** *World Patent Application WO 94/25591* 1994,
  127. Gouka RJ, Hessing JG, Punt PJ, Stam H, Musters W and van den Hondel CAMJJ **An expression system based on the promoter region of the *Aspergillus awamori* 1,4-beta-endoxylanase A gene.** *Appl Microbiol Biotechnol* 1996, **46**:28-35
  128. Frenken L, van Tuijl E, Bos JW, Müller WH, Verkleij AJ and Verrips CT **ScFv antibody fragments produced in *Saccharomyces cerevisiae* accumulate in the endoplasmic reticulum and the vacuole.** *Biological membranes: structure biogenesis and dynamics* (Edited by: NATO ASI Series) Springer-Verlag Berlin, Heidelberg 1994, **H82**:223-236
  129. Shusta EV, Raines-R T, Pluckthun A and Witttrup-K D **Increasing the secretory capacity of *Saccharomyces cerevisiae* for production of single chain antibody fragments.** *Nat Biotechnol* 1998, **16**:773-777
  130. Kauffman KJ, Pridgen EM, Doyle FJ, Dhurjati PS and Robinson AS **Decreased protein expression and intermittent recoveries in BiP levels result from cellular stress during heterologous protein expression in *Saccharomyces cerevisiae*.** *Biotechnol Prog* 2002, **18**:942-950
  131. Punt PJ, van Gemeren IA, Drint-Kuijvenhoven J, Hessing JG, van Muijlwijk-Harteveld GM, Beijersbergen A, Verrips CT and van den Hondel CA **Analysis of the role of the gene *bipA*, encoding the major endoplasmic reticulum chaperone protein in the secretion of homologous and heterologous proteins in black *Aspergilli*.** *Appl Microbiol Biotechnol* 1998, **50**:447-454
  132. Sotiriadis A, Keshavarz T and Keshavarz-Moore E **Factors Affecting the Production of a Single-Chain Antibody Fragment by *Aspergillus awamori* in a Stirred Tank Reactor.** *Biotechnol Prog* 2001, **17**:618-623
  133. Sagt CM, Muller WH, Boonstra J, Verkleij AJ and Verrips CT **Impaired secretion of a hydrophobic cutinase by *Saccharomyces cerevisiae* correlates with an increased association with immunoglobulin heavy-chain binding protein (BiP).** *Appl Environ Microbiol* 1998, **64**:316-324
  134. Frenken LG, van der Linden RH, Hermans PW, Bos JW, Ruuls RC, de Geus B and Verrips CT **Isolation of antigen specific llama V<sub>H</sub>H antibody fragments and their high level secretion by *Saccharomyces cerevisiae*.** *J Biotechnol* 2000, **78**:11-21
  135. Thomassen YE, Meijer W, Sierkstra L and Verrips CT **Large-scale production of V<sub>H</sub>H antibody fragments by *Saccharomyces cerevisiae*.** *Enzyme Microb Technol* 2002, **30**:273-278
  136. Verhoeyen ME, van der Logt CP, Beggs TS and Davis PJ **Antibody fragments for controlled delivery of therapeutic agents.** *Biochem Soc Trans* 1995, **23**:1067-1073

137. Akimoto K, Shinmen Y, Sumida M, Asami S, Amachi T, Yoshizumi H, Saeki Y, Shimizu S and Yamada H **Luminol chemiluminescence reaction catalyzed by a microbial peroxidase**. *Anal Biochem* 1990, **189**:182-185
138. Fukuyama K, Kunishima N, Amada F, Kubota T and Matsubara H **Crystal structures of cyanide- and triiodide-bound forms of *Arthromyces ramosus* peroxidase at different pH values. Perturbations of active site residues and their implication in enzyme catalysis**. *J Biol Chem* 1995, **270**:21884-21892
139. Kjalke M, Andersen MB, Schneider P, Christensen B, Schulein M and Welinder KG **Comparison of structure and activities of peroxidases from *Coprinus cinereus*, *Coprinus macrorhizus* and *Arthromyces ramosus***. *Biochim Biophys Acta* 1992, **1120**:248-256
140. Borrebaeck CA **Antibodies in diagnostics – from immunoassays to protein chips**. *Immunol Today* 2000, **21**:379-382
141. Holt LJ, Enever C, de Wildt RM and Tomlinson IM **The use of recombinant antibodies in proteomics**. *Curr Opin Biotechnol* 2000, **11**:445-449
142. Maras M, van Die I, Contreras R and van den Hondel CA **Filamentous fungi as production organisms for glycoproteins of biomedical interest**. *Glycoconj J* 1999, **16**:99-107
143. Wu XC, Ng SC, Near RI and Wong SL **Efficient production of a functional single-chain antidigoxin antibody via an engineered *Bacillus subtilis* expression-secretion system**. *Biotechnology (N Y)* 1993, **11**:71-76
144. Wu SC, Yeung JC, Duan Y, Ye R, Szarka SJ, Habibi HR and Wong SL **Functional production and characterization of a fibrin-specific single-chain antibody fragment from *Bacillus subtilis*: effects of molecular chaperones and a wall-bound protease on antibody fragment production**. *Appl Environ Microbiol* 2002, **68**:3261-3269
145. Binnie C, Cossar JD and Stewart DI **Heterologous biopharmaceutical protein expression in *Streptomyces***. *Trends Biotechnol* 1997, **15**:315-320
146. Ueda Y, Tsumoto K, Watanabe K and Kumagai I **Synthesis and expression of a DNA encoding the Fv domain of an anti-lysozyme monoclonal antibody, HyHEL10, in *Streptomyces lividans***. *Gene* 1993, **129**:129-134
147. Pschorr J, Bieseler B and Fritz HJ **Production of the immunoglobulin variable domain REIv via a fusion protein synthesized and secreted by *Staphylococcus carnosus***. *Biol Chem Hoppe Seyler* 1994, **375**:271-280
148. Kujau MJ, Hoischen C, Riesenberger D and Gumpert J **Expression and secretion of functional miniantibodies McPC603scFvDhlx in cell-wall-less L-form strains of *Proteus mirabilis* and *Escherichia coli*: a comparison of the synthesis capacities of L-form strains with an *E. coli* producer strain**. *Appl Microbiol Biotechnol* 1998, **49**:51-58
149. Rippmann JF, Klein M, Hoischen C, Brocks B, Rettig WJ, Gumpert J, Pfizenmaier K, Mattes R and Moosmayer D **Prokaryotic expression of single-chain variable-fragment (scFv) antibodies: secretion in L-form cells of *Proteus mirabilis* leads to active product and overcomes the limitations of periplasmic expression in *Escherichia coli***. *Appl Environ Microbiol* 1998, **64**:4862-4869
150. Neuberger MS **Making novel antibodies by expressing transfected immunoglobulin genes**. *Trends Biochem Sci* 1985, **9**:347-349
151. King DJ, Byron OD, Mountain A, Weir N, Harvey A, Lawson AD, Proudfoot KA, Baldock D, Harding SE and Yarranton GT **Expression, purification and characterization of B72.3 Fv fragments**. *Biochem J* 1993, **290**:723-729
152. Riechmann L, Foote J and Winter G **Expression of an antibody Fv fragment in myeloma cells**. *J Mol Biol* 1988, **203**:825-828
153. Dorai H, McCartney JE, Hudziak RM, Tai MS, Laminet AA, Houston LL, Huston JS and Oppermann H **Mammalian cell expression of single-chain Fv (scFv) antibody proteins and their C-terminal fusions with interleukin-2 and other effector domains**. *Biotechnology (N Y)* 1994, **12**:890-897
154. Jost CR, Kurucz I, Jacobus CM, Titus JA, George AJ and Segal DM **Mammalian expression and secretion of functional single-chain Fv molecules**. *J Biol Chem* 1994, **269**:26267-26273
155. Ailor E and Betenbaugh MJ **Modifying secretion and post-translational processing in insect cells**. *Curr Opin Biotechnol* 1999, **10**:142-145
156. Bei R, Schlom J and Kashmiri SV **Baculovirus expression of a functional single-chain immunoglobulin and its IL-2 fusion protein**. *J Immunol Methods* 1995, **186**:245-255
157. Carayannopoulos L, Max EE and Capra JD **Recombinant human IgA expressed in insect cells**. *Proc Natl Acad Sci U S A* 1994, **91**:8348-8352
158. Hasemann CA and Capra JD **High-level production of a functional immunoglobulin heterodimer in a baculovirus expression system**. *Proc Natl Acad Sci U S A* 1990, **87**:3942-3946
159. Kretzschmar T, Aoustin L, Zingel O, Marangi M, Vonach B, Towbin H and Geiser M **High-level expression in insect cells and purification of secreted monomeric single-chain Fv antibodies**. *J Immunol Methods* 1996, **195**:93-101
160. Mahiouz DL, Aichinger G, Haskard DO and George AJ **Expression of recombinant anti-E-selectin single-chain Fv antibody fragments in stably transfected insect cell lines**. *J Immunol Methods* 1998, **212**:149-160
161. Hiatt A, Cafferkey R and Bowdish K **Production of antibodies in transgenic plants**. *Nature* 1989, **342**:76-78
162. Fischer R, Vaquero-Martin C, Sack M, Drossard J, Emans N and Commandeur U **Towards molecular farming in the future: transient protein expression in plants**. *Biotechnol Appl Biochem* 1999, **30**:113-116
163. Kuroiwa Y, Kasinathan P, Choi YJ, Naeem R, Tomizuka K, Sullivan EJ, Knott JG, Duteau A, Goldsby RA, Osborne BA, Ishida I and Robl JM **Cloned transchromosomal calves producing human immunoglobulin**. *Nat Biotechnol* 2002, **20**:889-894
164. Little M, Kipriyanov SM, Le Gall F and Moldenhauer G **Of mice and men: hybridoma and recombinant antibodies**. *Immunol Today* 2000, **21**:364-370
165. Pollock DP, Kutzko JP, Birck-Wilson E, Williams JL, Echeland Y and Meade HM **Transgenic milk as a method for the production of recombinant antibodies**. *J Immunol Methods* 1999, **231**:147-157
166. Young MW, Meade H, Curling JM, Ziomek CA and Harvey M **Production of recombinant antibodies in the milk of transgenic animals**. *Res Immunol* 1998, **149**:609-610

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
http://www.biomedcentral.com/info/publishing\_adv.asp

